Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
29 août 2022 08h00 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Announces Repurchase of Convertible Notes
19 août 2022 07h30 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of...
Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
18 août 2022 08h00 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
03 août 2022 07h00 HE
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® non-GAAP adjusted net sales in PBC of $100.4 million; U.S. net sales of $71.8 million representing 5% growth over the prior year quarter Company reissues...
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
27 juil. 2022 08h00 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
07 juil. 2022 07h30 HE
|
Intercept Pharmaceuticals, Inc.
OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months (p<0.0001), consistent with the original REGENERATE analysis OCA 25...
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.
01 juil. 2022 16h01 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
21 juin 2022 07h30 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Provides Update on NASH Regulatory Timeline
06 juin 2022 06h30 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
03 juin 2022 07h30 HE
|
Intercept Pharmaceuticals, Inc.
COBALT study in advanced PBC, previously terminated early due to feasibility challenges, did not demonstrate a statistically significant difference in clinical endpoints between Ocaliva® and placebo ...